SG11202004471RA - Immunostimulatory oligonucleotides - Google Patents

Immunostimulatory oligonucleotides

Info

Publication number
SG11202004471RA
SG11202004471RA SG11202004471RA SG11202004471RA SG11202004471RA SG 11202004471R A SG11202004471R A SG 11202004471RA SG 11202004471R A SG11202004471R A SG 11202004471RA SG 11202004471R A SG11202004471R A SG 11202004471RA SG 11202004471R A SG11202004471R A SG 11202004471RA
Authority
SG
Singapore
Prior art keywords
immunostimulatory oligonucleotides
immunostimulatory
oligonucleotides
Prior art date
Application number
SG11202004471RA
Inventor
Thomas Ilg
Original Assignee
Bayer Animal Health Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Animal Health Gmbh filed Critical Bayer Animal Health Gmbh
Publication of SG11202004471RA publication Critical patent/SG11202004471RA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55555Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55561CpG containing adjuvants; Oligonucleotide containing adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/17Immunomodulatory nucleic acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/31Chemical structure of the backbone
    • C12N2310/315Phosphorothioates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/33Chemical structure of the base
    • C12N2310/334Modified C
    • C12N2310/33415-Methylcytosine
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/35Nature of the modification
    • C12N2310/351Conjugate
    • C12N2310/3515Lipophilic moiety, e.g. cholesterol
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00Applications; Uses
    • C12N2320/30Special therapeutic applications
    • C12N2320/31Combination therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11202004471RA 2017-12-15 2018-12-07 Immunostimulatory oligonucleotides SG11202004471RA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP17207750 2017-12-15
EP17207746 2017-12-15
EP17207740 2017-12-15
PCT/EP2018/084019 WO2019115402A1 (en) 2017-12-15 2018-12-07 Immunostimulatory oligonucleotides

Publications (1)

Publication Number Publication Date
SG11202004471RA true SG11202004471RA (en) 2020-06-29

Family

ID=66818991

Family Applications (3)

Application Number Title Priority Date Filing Date
SG11202004952UA SG11202004952UA (en) 2017-12-15 2018-12-07 Immunostimulatory oligonucleotides
SG11202004471RA SG11202004471RA (en) 2017-12-15 2018-12-07 Immunostimulatory oligonucleotides
SG11202004773SA SG11202004773SA (en) 2017-12-15 2018-12-07 Immunostimulatory compositions

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11202004952UA SG11202004952UA (en) 2017-12-15 2018-12-07 Immunostimulatory oligonucleotides

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11202004773SA SG11202004773SA (en) 2017-12-15 2018-12-07 Immunostimulatory compositions

Country Status (21)

Country Link
US (6) US20210062192A1 (en)
EP (3) EP3700564A1 (en)
JP (5) JP2021506246A (en)
KR (3) KR20200099556A (en)
CN (3) CN111801116A (en)
AU (3) AU2018385256A1 (en)
BR (3) BR112020011815A2 (en)
CA (3) CA3085657A1 (en)
CL (3) CL2020001561A1 (en)
CO (3) CO2020007102A2 (en)
CR (1) CR20200260A (en)
DO (3) DOP2020000113A (en)
IL (3) IL274975A (en)
MX (3) MX2020006246A (en)
PE (2) PE20210636A1 (en)
PH (3) PH12020550904A1 (en)
SG (3) SG11202004952UA (en)
TW (3) TW201936924A (en)
UY (3) UY38016A (en)
WO (3) WO2019115386A1 (en)
ZA (1) ZA202004317B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020310853A1 (en) 2019-07-05 2022-01-27 Tambo, Inc. Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy
CN113493790A (en) * 2020-04-01 2021-10-12 南京华普生物技术股份有限公司 CpG ODN with immunoregulation function and application thereof
JP2023537066A (en) 2020-08-07 2023-08-30 タンボ・インコーポレイテッド Trans-cyclooctene bioorthogonal agents and their use in cancer and immunotherapy
CN112159814B (en) * 2020-10-29 2023-05-16 中国农业科学院兰州兽医研究所 CpG oligodeoxynucleotide, preparation and use thereof
CN113797329A (en) * 2021-10-19 2021-12-17 启锰生物科技(江苏)有限公司 Vaccine adjuvant composition of bivalent manganese adjuvant and CpG adjuvant and preparation method thereof

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5719028A (en) * 1992-12-07 1998-02-17 Third Wave Technologies Inc. Cleavase fragment length polymorphism
DK0772619T4 (en) * 1994-07-15 2011-02-21 Univ Iowa Res Found Immunomodulatory oligonucleotides
US6693086B1 (en) 1998-06-25 2004-02-17 National Jewish Medical And Research Center Systemic immune activation method using nucleic acid-lipid complexes
SK287400B6 (en) * 1999-09-25 2010-08-09 University Of Iowa Research Foundation Immunostimulatory nucleic acid composition and the use thereof for stimulating an immune response
IL148844A0 (en) * 1999-09-27 2002-09-12 Coley Pharm Group Inc Methods related to immunostimulatory nucleic acid-induced interferon
KR100359753B1 (en) * 1999-12-21 2002-11-09 주식회사 제넥신 Modified phosphodiester CpG oligdeoxynucleotides conjugated with a dG run which have improved immunomodulatory activity and safety
AR040996A1 (en) 2002-08-19 2005-04-27 Coley Pharm Group Inc IMMUNE STIMULATING NUCLEIC ACIDS
JP4874801B2 (en) * 2003-06-11 2012-02-15 イデラ ファーマシューティカルズ インコーポレイテッド Stabilized immunomodulatory oligonucleotide
WO2005030259A2 (en) 2003-09-25 2005-04-07 Coley Pharmaceutical Group, Inc. Nucleic acid-lipophilic conjugates
WO2005042018A2 (en) * 2003-10-30 2005-05-12 Coley Pharmaceutical Gmbh C-class oligonucleotide analogs with enhanced immunostimulatory potency
DE602004009818T2 (en) * 2003-11-05 2008-09-18 Intercell Ag COMPOSITIONS DERIVED FROM MELITTIN AND CONTAINING PEPTIDES, AND METHOD FOR POTENTIATING IMMUNE REACTIONS AGAINST TARGET ANTIGENES
KR100558851B1 (en) * 2004-01-08 2006-03-10 학교법인연세대학교 Modified CpG oligodeoxynucleotide with improved immunoregulatory function
JP5014122B2 (en) * 2004-05-06 2012-08-29 アメリカ合衆国 Methods and compositions for the treatment of uveitis
WO2006091915A2 (en) * 2005-02-24 2006-08-31 Coley Pharmaceutical Group, Inc. Immunostimulatory oligonucleotides
EP1764108A1 (en) * 2005-09-14 2007-03-21 Gunther Hartmann Compositions comprising immunostimulatory RNA oligonucleotides and methods for producing said RNA oligonucleotides
PT2405002E (en) * 2006-02-15 2015-01-05 Adiutide Pharmaceuticals Gmbh Compositions and methods for oligonucleotide formulations
CN100418583C (en) * 2006-02-21 2008-09-17 朱鸿飞 Medicine composition for preventing and treating mammitis
US20080124366A1 (en) * 2006-08-06 2008-05-29 Ohlfest John R Methods and Compositions for Treating Tumors
CN102851295B (en) * 2006-08-28 2015-01-07 长春华普生物技术有限公司 Toll-like receptor regulatory oligonucleotide and application thereof
KR101251707B1 (en) 2006-09-27 2013-04-11 콜리 파마슈티칼 게엠베하 CpG oligonucleotide analogs containing hydrophobic T analogs with enhanced immunostimulatory activity
US8128944B2 (en) * 2007-08-13 2012-03-06 Coley Pharmaceutical Gmbh RNA sequence motifs in the context of defined internucleotide linkages inducing specific immune modulatory profiles
EP2427472B1 (en) 2009-05-05 2016-06-22 Miragen Therapeutics Lipophilic polynucleotide conjugates
RU2570732C9 (en) * 2009-05-14 2016-09-10 Байер Интеллектуэль Проперти Гмбх Enhanced immune response in bird species
ES2683316T3 (en) 2010-05-28 2018-09-26 Zoetis Belgium S.A. Vaccines that comprise cholesterol and CpG as the only adjuvant transporter molecules
DK2654785T3 (en) * 2010-12-22 2019-06-24 Bayer Ip Gmbh Increased immune response in cattle breeds
EP2471926A3 (en) * 2010-12-30 2012-07-11 Intervet International BV Immunostimulatory oligodeoxynucleotides
RU2584588C2 (en) * 2011-05-26 2016-05-20 Интервет Интернэшнл Б.В. Immunostimulating oligodeoxynucleotides
EP2714907B1 (en) * 2011-05-26 2016-06-15 Intervet International B.V. Immunostimulatory oligodeoxynucleotides
JP6375289B2 (en) 2012-04-05 2018-08-15 マサチューセッツ インスティテュート オブ テクノロジー Immune stimulating composition and method of use thereof
AR091569A1 (en) 2012-06-28 2015-02-11 Intervet Int Bv TOLL TYPE RECEIVERS
US20150301058A1 (en) * 2012-11-26 2015-10-22 Caris Science, Inc. Biomarker compositions and methods
JP6649248B2 (en) 2013-05-01 2020-02-19 レグルス セラピューティクス インコーポレイテッド Compounds and methods for enhancing cellular uptake
TWI535451B (en) * 2013-07-19 2016-06-01 財團法人國家衛生研究院 Cpg-oligodeoxynucleotide, immunogenic composition comprising the same, and use of preparation of medicament for treatment in stimulating immune response
AR097029A1 (en) * 2013-07-26 2016-02-17 Intervet Int Bv ACCELERATION OF THE IMMUNE RESPONSE INDUCED BY VECTOR VIRUS IN BIRDS, COMPOSITION, USE, VACCINATION METHOD AND METHOD FOR ACCELERATING THE IMMUNE RESPONSE
GB2517700A (en) * 2013-08-27 2015-03-04 Lgc Ltd Oligonucleotides comprising a secondary structure and uses thereof
CA2940794C (en) * 2014-02-28 2022-05-31 Bayer Animal Health Gmbh Immunostimulatory plasmids
US10888603B2 (en) * 2016-02-12 2021-01-12 The Board Of Trustees Of The Leland Stanford Junior University Methods of treating cancer cells expressing tumor-associated integrins

Also Published As

Publication number Publication date
AU2018382419A1 (en) 2020-06-04
MX2020006243A (en) 2020-09-03
JP2021506245A (en) 2021-02-22
EP3694549A1 (en) 2020-08-19
CL2020001562A1 (en) 2020-11-06
CL2020001560A1 (en) 2020-11-06
US11542507B2 (en) 2023-01-03
CN111447949A (en) 2020-07-24
EP3701032A1 (en) 2020-09-02
CA3085657A1 (en) 2019-06-20
UY38015A (en) 2019-06-28
KR20200098637A (en) 2020-08-20
IL274975A (en) 2020-07-30
DOP2020000113A (en) 2020-08-31
PE20210636A1 (en) 2021-03-23
JP2021506246A (en) 2021-02-22
JP7273040B2 (en) 2023-05-12
CL2020001561A1 (en) 2020-11-06
BR112020011815A2 (en) 2020-11-17
CO2020007102A2 (en) 2020-06-19
WO2019115386A1 (en) 2019-06-20
WO2019115385A1 (en) 2019-06-20
IL275217A (en) 2020-07-30
MX2020006246A (en) 2020-09-03
CN111801419A (en) 2020-10-20
CO2020007100A2 (en) 2020-06-19
SG11202004773SA (en) 2020-06-29
JP7458977B2 (en) 2024-04-01
BR112020011838A2 (en) 2020-11-24
US20230332162A1 (en) 2023-10-19
CN111801116A (en) 2020-10-20
US20240076681A1 (en) 2024-03-07
CR20200260A (en) 2020-08-01
JP2023156485A (en) 2023-10-24
RU2020122553A (en) 2022-01-17
TW201940192A (en) 2019-10-16
US20230174990A1 (en) 2023-06-08
AU2018385257A1 (en) 2020-06-18
RU2020122545A3 (en) 2022-05-04
UY38014A (en) 2019-06-28
CO2020007120A2 (en) 2020-06-19
ZA202004317B (en) 2023-05-31
AU2018385256A1 (en) 2020-06-11
BR112020011845A2 (en) 2020-11-24
IL275086A (en) 2020-07-30
KR20200099556A (en) 2020-08-24
US20210062192A1 (en) 2021-03-04
US20210170020A1 (en) 2021-06-10
US11932857B2 (en) 2024-03-19
TW201936924A (en) 2019-09-16
DOP2020000107A (en) 2020-08-31
KR20200098638A (en) 2020-08-20
WO2019115402A1 (en) 2019-06-20
UY38016A (en) 2019-06-28
DOP2020000106A (en) 2020-08-31
MX2020006244A (en) 2020-09-03
US20200385733A1 (en) 2020-12-10
JP2023153970A (en) 2023-10-18
TWI821224B (en) 2023-11-11
WO2019115386A9 (en) 2020-07-23
PH12020550904A1 (en) 2021-05-17
JP2021506779A (en) 2021-02-22
CA3085661A1 (en) 2019-06-20
TW201936923A (en) 2019-09-16
PH12020550903A1 (en) 2021-05-17
CA3085575A1 (en) 2019-06-20
RU2020122545A (en) 2022-01-19
SG11202004952UA (en) 2020-06-29
EP3700564A1 (en) 2020-09-02
PE20210635A1 (en) 2021-03-23
PH12020550906A1 (en) 2021-05-17

Similar Documents

Publication Publication Date Title
IL268422A (en) Targeted oligonucleotides
HK1258758A1 (en) Branched oligonucleotides
GB201806688D0 (en) No details
HK1257273A1 (en) Combination comprising immunostimulatory oligonucleotides
GB201803663D0 (en) No details
GB201801258D0 (en) No details
GB202000441D0 (en) No details
GB201721011D0 (en) No details
GB201503408D0 (en) Oligonucleotides
IL275217A (en) Immunostimulatory oligonucleotides
GB201801628D0 (en) No details
EP3684343C0 (en) Improved supraparticles
GB201807647D0 (en) No details
GB201504124D0 (en) Oligonucleotides
IL272526A (en) Improved endoinulinases
SG10201913477UA (en) G-quadruplex-containing antisense oligonucleotides
SG10201609048RA (en) Antisense oligonucleotides
GB201717719D0 (en) No details
EP3238727A4 (en) Non-aggregating immunostimulatory oligonucleotides
GB201811353D0 (en) No details
GB201802344D0 (en) No details
GB201720890D0 (en) No details
GB201801239D0 (en) No details
GB201709043D0 (en) No details
GB201714330D0 (en) Oligonucleotides